Clinical Trials

Retinal Diagnostic Center is committed to giving our patients the most up-to-date medical care possible. Our participation in clinical trials affords our patients the opportunity to receive state-of-the art-treatment or medication, before these options are available commercially. We choose to participate only in clinical trials that may offer superior treatment, in comparison to currently available treatments, and clinical trials to treat conditions that currently have no approved treatment.

Our research department is headed by Amr Dessouki, M.D. who has been the principal investigator for several national and international multi-center clinical trials. He works closely with the American Institute of Research, the Diabetic Retinopathy Clinical Research Network, FDA and several pharmaceutical companies. Drs. Monahan, Chen, Chow, He, and Gao participate as Co-investigators.

If one of our doctors believes you may benefit from being involved in a clinical trial, he will offer you the opportunity to meet with Dr. Dessouki, Dr. Chow, or Dr. He and our research team. During this visit, you will undergo a detailed explanation of the trial and the consenting process. If you choose to participate, you will be scheduled for a screening visit, which involves an extensive eye examination and general medical history to determine if you are eligible for the study. Participation in these trials is completely voluntary and free. You will not be charged for any visit or treatment related to the trial.

Our research coordinator Lynise Cummins can be reached at (408) 559-0666, ext 119, Monday through Friday from 9:00 am to 5:00 pm. If you have any questions related to the trials please feel free to contact her.

Current clinical trials:

Study Name: Ascent

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

Study Sponsor: RegenXBio

Study Status: Currently enrolling patients

Study Name: Atmosphere

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

Study Sponsor: RegenXBio

Study Status: Currently enrolling patients

Study Name: Altitude Part 2

A Phase 2, Randomized, Controlled, Dose-escalation Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema

Study Sponsor: RegenXBio

Study Status: Currently enrolling patients

Study Name: Crimson

A Multicenter Randomized, Sham-Controlled (and Active Controlled in the USA), Double-Masked, 72-Week Trial to Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal BI 764524 in Patients With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Study Sponsor: Boehringer Ingelheim

Study Status: Currently enrolling patients

This is a list of past clinical trials that Retinal Diagnostic Center was a part of (you can find more detailed information on the web at clinicaltrials.gov):

Study Name: Elevatum

A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Closed

Study Name: Gale

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Sponsor: Apellis Pharmaceuticals

Study Status: Closed

Past Studies:

Study Name: Davio2

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

Study Sponsor: EyePoint Pharmaceuticals, Inc.

Study Status: Completed

Study Name: Longitude

A Longitudinal, Biomarker Study of Anti-VEGF, to Explore the Relationship Between Aqueous Humor Composition and Multimodal Retinal Imaging in Neovascular Age-Related macular Degeneration and Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Comino

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Balaton

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Shore

A Phase 3, Multicenter, Double-Masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration (nAMD)

Study Sponsor: Opthea

Study Status: Completed

Study Name: Mylight

A 52-Week Multicenter, Randomized, Double-Masked 2-Arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea, Administered Intravitreally, In Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: Sandoz Biopharmaceuticals

Study Status: Completed

Study Name: Photon

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema

Study Sponsor: Regeneron Pharmaceuticals

Study Status: Completed

Study Name: GEM-CL-10311

A Multicenter, Multiple-Dose Study in Neovascular Age-Related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct Standard of Care Aflibercept Therapy

Study Sponsor: Gemini Therapeutics

Study Status: Completed

Study Name: Rhone-X

A Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Avonelle-X

A Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: F. Hoffmann-La Roche Ltd

Study Status: Completed

Study Name: Gather2

A Phase 3 Multicenter, Randomized, Double-Masked, Sham- Controlled, Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Sponsor: IVERIC bio

Study Status: Completed

Study Name: Catalina

A Phase 2 Multicenter, Randomized, Double-Masked, Sham- Controlled study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Study Sponsor: NGM Biopharmaceuticals

Study Status: Completed

Study Name: SCD411-CP101

A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea in Subjects with Neovascular Age-Related Macular Degeneration

Study Sponsor: SamChunDang Pharm Co

Study Status: Completed

Study Name: Oaks

A Phase III, Multi-Center, Randomized, Double-Masked, Sham- Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.

Study Sponsor: Apellis Pharmaceuticals

Study Status: Completed

Study Name: Tenaya

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration

Study Sponsor: F. Hoffmann-La Roche Ltd.

Study Status: Completed

Study Name: Yosemite

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema

Study Sponsor: F. Hoffmann-La Roche Ltd.

Study Status: Completed